Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precancerous Conditions 1Melanoma 1Inflammatory Bowel Diseases 1Hepatitis C 1Hematologic Neoplasms 1Granulomatous Disease, Chronic 1Fatigue 1Crohn Disease 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 14fludarabine 10fludarabine phosphate 8Whole-Body Irradiation 7thymoglobulin 5Thiotepa 5Tacrolimus 5Stem Cell Transplantation 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Azacitidine 5venetoclax 4Standard of Care 4Radiotherapy 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Melphalan 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 4Rituximab 3Mesna 3Leucovorin 3Dexamethasone 3Calcium Dobesilate 3Alemtuzumab 3ruxolitinib 2ceritinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hematologic Neoplasms × Infliximab × Clear all
NCT04438382 2026-05-15

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Eastern Cooperative Oncology Group

Phase 2 Terminated
1 enrolled 1 chart
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡